These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 38688749)

  • 21. The Forgotten Lipids: Triglycerides, Remnant Cholesterol, and Atherosclerotic Cardiovascular Disease Risk.
    Sandesara PB; Virani SS; Fazio S; Shapiro MD
    Endocr Rev; 2019 Apr; 40(2):537-557. PubMed ID: 30312399
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Elevated triglycerides and low high-density lipoprotein cholesterol level as marker of very high risk in type 2 diabetes.
    Hermans MP; Valensi P
    Curr Opin Endocrinol Diabetes Obes; 2018 Apr; 25(2):118-129. PubMed ID: 29493554
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dyslipidemias in patients with diabetes mellitus: classification and risks and benefits of therapy.
    Oki JC
    Pharmacotherapy; 1995; 15(3):317-37. PubMed ID: 7667166
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Triglycerides to high-density lipoprotein-cholesterol ratio, glycemic control and cardiovascular risk in obese patients with type 2 diabetes.
    Quispe R; Martin SS; Jones SR
    Curr Opin Endocrinol Diabetes Obes; 2016 Apr; 23(2):150-6. PubMed ID: 26863278
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Atherosclerotic risk factors in cardiovascular disease.
    LaRosa JC
    J Reprod Med; 1986 Sep; 31(9 Suppl):906-12. PubMed ID: 3772910
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Lipoprotein physiology in nondiabetic and diabetic states. Relationship to atherogenesis.
    Ginsberg HN
    Diabetes Care; 1991 Sep; 14(9):839-55. PubMed ID: 1959476
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of evolocumab in individuals with type 2 diabetes with and without atherogenic dyslipidemia: An analysis from BANTING and BERSON.
    Lorenzatti AJ; Monsalvo ML; López JAG; Wang H; Rosenson RS
    Cardiovasc Diabetol; 2021 Apr; 20(1):94. PubMed ID: 33941192
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cardiometabolic Risk Factors Associated With Type 2 Diabetes Mellitus: A Mechanistic Insight.
    Chakraborty S; Verma A; Garg R; Singh J; Verma H
    Clin Med Insights Endocrinol Diabetes; 2023; 16():11795514231220780. PubMed ID: 38148756
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Lipoproteins, apolipoproteins, and low-density lipoprotein size among diabetics in the Framingham offspring study.
    Siegel RD; Cupples A; Schaefer EJ; Wilson PW
    Metabolism; 1996 Oct; 45(10):1267-72. PubMed ID: 8843183
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Metabolism and Modification of Apolipoprotein B-Containing Lipoproteins Involved in Dyslipidemia and Atherosclerosis.
    Morita SY
    Biol Pharm Bull; 2016; 39(1):1-24. PubMed ID: 26725424
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Lowering Targeted Atherogenic Lipoprotein Cholesterol Goals for Patients at "Extreme" ASCVD Risk.
    Rosenblit PD
    Curr Diab Rep; 2019 Nov; 19(12):146. PubMed ID: 31754844
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Apolipoprotein status in type 2 diabetes mellitus and its complications (Review).
    Zhang P; Gao J; Pu C; Zhang Y
    Mol Med Rep; 2017 Dec; 16(6):9279-9286. PubMed ID: 29152661
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Association between lipids and apolipoproteins on type 2 diabetes risk; moderating effects of gender and polymorphisms; the ATTICA study.
    Mellor DD; Georgousopoulou EN; D'Cunha NM; Naumovski N; Chrysohoou C; Tousoulis D; Pitsavos C; Panagiotakos DB;
    Nutr Metab Cardiovasc Dis; 2020 May; 30(5):788-795. PubMed ID: 32127339
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The metabolic and pharmacologic bases for treating atherogenic dyslipidaemia.
    Chan DC; Barrett PH; Watts GF
    Best Pract Res Clin Endocrinol Metab; 2014 Jun; 28(3):369-85. PubMed ID: 24840265
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Remnant lipoproteins and atherosclerotic cardiovascular disease.
    Tada H; Nohara A; Inazu A; Mabuchi H; Kawashiri MA
    Clin Chim Acta; 2019 Mar; 490():1-5. PubMed ID: 30553862
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Low-density lipoprotein cholesterol-to-apolipoprotein B ratio as a potential indicator of LDL particle size and plasma atherogenicity in type 2 diabetes.
    Viktorinova A; Malickova D; Svitekova K; Choudhury S; Krizko M
    Diabetes Res Clin Pract; 2021 Jun; 176():108858. PubMed ID: 34015391
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Abnormalities in lipoprotein metabolism in hemodialysis patients.
    Königer M; Quaschning T; Wanner C; Schollmeyer P; Krämer-Guth A
    Kidney Int Suppl; 1999 Jul; 71():S248-50. PubMed ID: 10412790
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Glycated apolipoprotein B decreases after bariatric surgery in people with and without diabetes: A potential contribution to reduction in cardiovascular risk.
    Iqbal Z; Bashir B; Adam S; Ho JH; Dhage S; Azmi S; Ferdousi M; Yusuf Z; Donn R; Malik RA; Syed A; Ammori BJ; Heald A; Durrington PN; Soran H
    Atherosclerosis; 2022 Apr; 346():10-17. PubMed ID: 35247628
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Postprandial lipoprotein metabolism in normotriglyceridemic non-insulin-dependent diabetic patients: influence of apolipoprotein E polymorphism.
    Reznik Y; Pousse P; Herrou M; Morello R; Mahoudeau J; Drosdowsky MA; Fradin S
    Metabolism; 1996 Jan; 45(1):63-71. PubMed ID: 8544779
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Causes of dysregulation of lipid metabolism in chronic renal failure.
    Vaziri ND
    Semin Dial; 2009; 22(6):644-51. PubMed ID: 20017835
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.